Skip to main content

FDA Clears Bruker's MALDI Biotyper for Clinical Microbiology Use

NEW YORK (GenomeWeb News) – The Food and Drug Administration has granted 510(k) clearance to Bruker's MALDI Biotyper CA system for identifying gram negative bacterial colonies cultured from human specimens, Bruker said today.

The MALDI Biotyper instrument uses proteomic fingerprinting to enable molecular identification and taxonomical classification of microorganisms including bacteria, yeasts, and fungi. They can be used in routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer safety and quality control, as well as in marine microbiology.

The system includes the microflex MALDI-TOF mass spectrometer, software, IVD labeled reagents, a 48 spot MALDI target, and a library of microorganism reference spectra. Bruker said that it conducted a multisite clinical trial comparing the Biotyper with 16S ribosomal RNA gene sequencing, and the overall accuracy of the instrument is comparable with nucleic acid sequencing.

As GenomeWeb Daily News sister publication ProteoMonitor reported this summer, MALDI mass spectrometry has been poised to expand further into clinical microbiology markets, but the two main players in this field – Bruker and BioMérieux – were awaiting FDA approval for the use of these tools in clinical diagnostics.

BioMérieux received the FDA nod for its Vitek MS Microbiology System three months ago.

The MALDI Biotyper has been available for clinical microbiology use in Europe, as well as Canada, Argentina, Mexico, Colombia, Ecuador, Japan, Hong Kong, Singapore, Malaysia, and Taiwan, Bruker said.

"With clearance from the US FDA to market the MALDI Biotyper CA System, we expand our market reach into the largest clinical market in the world, with expected significant improvements in outcomes and reductions in the cost of healthcare," Bruker President and CEO Frank Laukien said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.